| dc.creator | Zaldívar Vázquez, Lorena | |
| dc.creator | Meneses Calderón, José | |
| dc.creator | Ochoa Morales, Carlos Felipe | |
| dc.creator | Mendieta Zerón, Hugo | |
| dc.date | 2022-09-21T22:21:34Z | |
| dc.date | 2022-09-21T22:21:34Z | |
| dc.date | 2022-09-16 | |
| dc.date.accessioned | 2022-10-13T00:31:35Z | |
| dc.date.available | 2022-10-13T00:31:35Z | |
| dc.identifier | 2012-8169 | |
| dc.identifier | http://hdl.handle.net/20.500.11799/113494 | |
| dc.identifier.uri | https://repositorioslatinoamericanos.uchile.cl/handle/2250/4156500 | |
| dc.description | SARS-CoV-2 leads to an inflammatory and fibrotic state in the lungs which can be the cause of death and even in those who survive cause a functional limitation. A male patient of 28 years with COVID-19 was treated with nitazoxanide 500 mg 6 hourly, ibuprofen 500 mg 8 hourly, levofloxacin 500 mg and vitamin D 4,000 IU 24 hourly, and pirfenidone (K-LP) 1,200 mg 12 hourly. The patient was ventilated and extubated after 13 days in the intensive care unit. He was then immersed in a strict rehabilitation programme based on re-teaching the diaphragmatic respiratory pattern. Pirfenidone at a dose of 1,200 mg twice a day could be considered as a valid option to reduce lung fibrosis caused by the SARS-CoV-2 virus. To ensure optimal recovery, pulmonary rehabilitation therapy should be added to the management. | |
| dc.language | eng | |
| dc.publisher | Sri Lankan Society for Microbiology | |
| dc.relation | 12 | |
| dc.relation | 2 | |
| dc.rights | openAccess | |
| dc.rights | http://creativecommons.org/licenses/by/4.0 | |
| dc.subject | Case report | |
| dc.subject | COVID-19 | |
| dc.subject | Lung fibrosis | |
| dc.subject | Pirfenidone | |
| dc.subject | Rehabilitation | |
| dc.subject | MEDICINA Y CIENCIAS DE LA SALUD | |
| dc.title | COVID-19 lung lesion treated with pirfenidone and effective rehabilitation: A Case Report | |
| dc.type | Artículo | |
